分子細胞遺伝学の世界市場規模：製品別、技術別、用途別、地域別、範囲および予測

分子細胞遺伝学の市場規模と予測

分子細胞遺伝学市場規模は、2024年に25億7,000万米ドルと評価され、2024年から2031年にかけてCAGR 10%で成長し、2031年には51億5,000万米ドルに達すると予測されています。分子細胞遺伝学では、蛍光in situハイブリダイゼーション（FISH）、比較ゲノムハイブリダイゼーション（CGH）、分子クローニングなどの分子技術を使用して染色体を研究します。これにより、研究者は染色体異常、遺伝子マッピングを分析し、染色体内の遺伝物質の構成を理解することができます。分子細胞遺伝学的技術は、染色体異常によって引き起こされる遺伝性疾患を診断するために、臨床の場で広く用いられています。例えばFISHは、ダウン症のような疾患や様々ながんに関連する特定の遺伝子配列を検出することができます。がん細胞における染色体異常を理解することは、がんの診断、予後、治療に極めて重要です。CGHとFISHは、がんの進行や薬剤耐性を引き起こす遺伝的変化を検出するために使用されます。

出生前診断では、FISHやアレイCGHなどの技術を用いて胎児の染色体異常を検出し、重要な役割を果たしています。

ゲノムマッピングやゲノムの構造変異の理解にも役立ちます。これは進化生物学、集団遺伝学、形質や疾患の遺伝的基盤の研究に重要です。

分子技術やイメージング技術の継続的な進歩は、分子細胞遺伝学の分解能、精度、効率を高めるであろう。これにより、染色体の構造と機能をより詳細に分析できるようになります。

分子細胞遺伝学の世界市場力学

主な市場促進要因

技術の進歩：

FISHやCGHなどのゲノム技術における絶え間ない技術革新は、染色体分析の精度、感度、効率を向上させ、臨床診断や研究における応用領域を拡大し、市場の成長を可能にします。

遺伝性疾患とがんの有病率の増加：

世界の遺伝性疾患やがんの罹患率の増加は、染色体異常を検出し、個別化された治療戦略を導くことができる精密な診断ツールに対する需要を煽る。

個別化医療へのシフト：

分子細胞遺伝学は、疾患感受性や治療効果に影響を与える遺伝子マーカーや異常の同定を可能にすることで、個別化医療において極めて重要な役割を果たしています。

ヘルスケア支出の増加：

世界のヘルスケア支出の増加は、分子細胞遺伝学を含む高度診断技術への投資を支え、市場成長を促進します。

戦略的コラボレーションとパートナーシップ：

学界、研究機関、業界関係者の協力により、革新的な分子細胞遺伝学的ソリューションの開発が促進され、市場開拓が進みます。

支持的な規制環境：

良好な規制方針とガイドラインにより、分子細胞遺伝学関連製品の承認プロセスが合理化され、投資と市場成長が促進されます。

早期診断と積極的ヘルスケアへの注力：

分子細胞遺伝学的検査は、遺伝性疾患やがんの早期発見を可能にし、臨床医にタイムリーな介入を開始させ、患者の転帰を改善する力を与えます。

主な課題

技術の複雑さとコスト：

FISHやCGHのような高度な分子細胞遺伝学的技術は、洗練された機器、特殊な試薬、熟練した人材を必要とし、全体的なコストを増加させるため、市場の成長を妨げています。

解釈と標準化：

分子細胞遺伝学によって生成された複雑な染色体データの解析と解釈は、プロトコール、データの解釈、検査室間の標準化にばらつきがあるため課題となります。

規制上のハードル：

新しい分子細胞遺伝学的検査法に対する厳しい規制要件と長い承認プロセスは、市場参入と技術革新を遅らせる可能性があります。

償還の問題：

分子細胞遺伝学的検査に対する限られた償還政策と償還率のばらつきが、ヘルスケア提供者の採用を妨げ、市場成長を阻害する可能性があります。

臨床診療との統合：

分子細胞遺伝学的検査を既存の臨床ワークフローやヘルスケアシステムに統合することは困難であり、インフラ投資やワークフローの調整が必要となります。

教育および認識の障壁：

ヘルスケアプロバイダーや患者における分子細胞遺伝学的技術に対する認識や理解が限定的であることが、採用や利用の妨げになる可能性があります。

競合情勢：

市場参入企業間の激しい競合と急速な技術進歩により、市場シェアと収益性を維持するためには継続的な技術革新と差別化が必要となります。

主要動向

技術の進歩：

次世代シーケンシング（NGS）、シングルセルシーケンシング、デジタルPCRなどのゲノム技術の絶え間ない革新により、分子細胞遺伝学的アッセイの感度、分解能、スループットが向上しています。

マルチオミクスアプローチの統合：

細胞遺伝学的データとゲノム、トランスクリプトーム、エピゲノムデータ（マルチオミクス）を組み合わせることで、遺伝性疾患やがんの包括的な理解が得られ、個別化医療が促進されます。

リキッドバイオプシーの台頭：

循環腫瘍DNA（ctDNA）解析や無細胞DNA（cfDNA）シーケンシングを含むリキッドバイオプシー技術は、がんにおける染色体異常を非侵襲的に検出・モニタリングするためにますます使用されるようになっています。

自動化とロボット工学：

分子細胞遺伝学検査室における自動化とロボティクスの導入は、ワークフローを合理化し、作業時間を短縮し、アッセイの再現性と拡張性を向上させる。

精密医療への取り組み：

精密医療への取り組みが重視されるようになり、特定の遺伝子マーカーを同定して標的治療の指針となる分子細胞遺伝学検査への需要が高まっています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 分子細胞遺伝学市場：製品別

• キット・試薬
• 器具
• 消耗品
• ソフトウェアとサービス

第5章 分子細胞遺伝学市場：技術別

• 蛍光In Situハイブリダイゼーション（FISH）
• 比較ゲノムハイブリダイゼーション（CGH）
• ゲノムIn Situハイブリダイゼーション（GISH）
• アレイ比較ゲノムハイブリダイゼーション（ACGH）

第6章 分子細胞遺伝学市場：用途別

• 遺伝子疾患
• 腫瘍学
• 個別化医療

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Agilent Technologies, Inc.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Oxford Gene Technology IP Limited
• Leica Biosystems Nussloch GmbH
• CytoTest Inc.
• Cytognomix, Inc.
• Bionano Genomics

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Molecular Cytogenetics Market Size And Forecast

Molecular Cytogenetics Market size was valued at USD 2.57 Billion in 2024 and is projected to reach USD 5.15 Billion by 2031, growing at a CAGR of 10% from 2024 to 2031. Molecular cytogenetics involves the use of molecular techniques such as fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and molecular cloning to study chromosomes. It allows researchers to analyze chromosomal abnormalities, gene mapping, and understand the organization of genetic material within chromosomes. Molecular cytogenetic techniques are extensively used in clinical settings to diagnose genetic disorders caused by chromosomal abnormalities. FISH, for example, can detect specific genetic sequences associated with diseases like Down syndrome or various cancers. Understanding chromosomal abnormalities in cancer cells is crucial for cancer diagnosis, prognosis, and treatment. CGH and FISH are used to detect genetic changes that drive cancer progression and drug resistance.

It plays a vital role in prenatal diagnosis, detecting chromosomal abnormalities in fetuses using techniques like FISH or array CGH.

It helps in genome mapping and understanding the structural variations in genomes. This is important for studying evolutionary biology, population genetics, and the genetic basis of traits and diseases.

Continued advancements in molecular techniques and imaging technologies will enhance the resolution, accuracy, and efficiency of molecular cytogenetics. This will allow for more detailed analysis of chromosomal structures and functions.

Global Molecular Cytogenetics Market Dynamics

The key market dynamics that are shaping the global molecular cytogenetics market include:

Key Market Drivers

Technological Advancements:

Continuous innovation in genomic technologies, such as FISH and CGH, enhances the accuracy, sensitivity, and efficiency of chromosomal analysis, thereby expanding the application areas in clinical diagnostics and research, this enables growth of the market.

Increasing Prevalence of Genetic Disorders and Cancer:

The rising incidence of genetic diseases and cancers worldwide fuels the demand for precise diagnostic tools that can detect chromosomal abnormalities and guide personalized treatment strategies.

Shift towards Personalized Medicine:

Molecular cytogenetics plays a pivotal role in personalized medicine by enabling the identification of genetic markers and abnormalities that influence disease susceptibility and treatment response.

Growing Healthcare Expenditure:

Rising healthcare spending globally supports investments in advanced diagnostic technologies, including molecular cytogenetics, driving market growth.

Strategic Collaborations and Partnerships:

Collaborative efforts between academia, research institutions, and industry players facilitate the development of innovative molecular cytogenetic solutions and expand market reach.

Supportive Regulatory Environment:

Favorable regulatory policies and guidelines streamline the approval process for molecular cytogenetic products, encouraging investment and market growth.

Focus on Early Diagnosis and Proactive Healthcare:

Molecular cytogenetic tests enable early detection of genetic disorders and cancers, empowering clinicians to initiate timely interventions and improve patient outcomes.

Key Challenges:

Complexity and Cost of Technology:

Advanced molecular cytogenetic techniques such as FISH and CGH require sophisticated equipment, specialized reagents, and skilled personnel, increasing overall costs which is hindering the growth of the market.

Interpretation and Standardization:

Analyzing and interpreting complex chromosomal data generated by molecular cytogenetics poses challenges due to variability in protocols, data interpretation, and standardization across laboratories.

Regulatory Hurdles:

Stringent regulatory requirements and lengthy approval processes for new molecular cytogenetic assays can delay market entry and innovation.

Reimbursement Issues:

Limited reimbursement policies and variability in reimbursement rates for molecular cytogenetic tests may hinder adoption among healthcare providers and hamper market growth.

Integration with Clinical Practice:

Integrating molecular cytogenetic tests into existing clinical workflows and healthcare systems can be challenging, requiring infrastructure investments and workflow adjustments.

Educational and Awareness Barriers:

Limited awareness and understanding of molecular cytogenetic technologies among healthcare providers and patients may hinder adoption and utilization.

Competitive Landscape:

Intense competition among market players and rapid technological advancements necessitate continuous innovation and differentiation to maintain market share and profitability.

Key Trends

Advancements in Technology:

Continuous innovation in genomic technologies, such as next-generation sequencing (NGS), single-cell sequencing, and digital PCR, is enhancing the sensitivity, resolution, and throughput of molecular cytogenetic assays.

Integration of Multi-Omics Approaches:

Combining cytogenetic data with genomic, transcriptomic, and epigenomic data (multi-omics) provides a comprehensive understanding of genetic disorders and cancers, facilitating personalized medicine.

Rise of Liquid Biopsies:

Liquid biopsy techniques, including circulating tumor DNA (ctDNA) analysis and cell-free DNA (cfDNA) sequencing, are increasingly used for non-invasive detection and monitoring of chromosomal abnormalities in cancers.

Automation and Robotics:

Adoption of automation and robotics in molecular cytogenetics laboratories streamlines workflows, reduces hands-on time, and improves assay reproducibility and scalability.

Precision Medicine Initiatives:

Growing emphasis on precision medicine initiatives is driving demand for molecular cytogenetic tests that can identify specific genetic markers and guide targeted therapies.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Molecular Cytogenetics Market Regional Analysis

Here is a more detailed regional analysis of the global molecular cytogenetics market:

North America

North America is expected to dominate the molecular cytogenetics market. The region boasts well-established healthcare facilities equipped with state-of-the-art diagnostic technologies. This infrastructure supports the widespread adoption of molecular cytogenetic tests across various clinical settings, from hospitals to research laboratories.

The United States and Canada have robust regulatory agencies like the FDA (Food and Drug Administration) and Health Canada, respectively. These agencies enforce clear guidelines and stringent regulatory standards for the approval and commercialization of molecular cytogenetic products. This regulatory clarity accelerates the market entry of new technologies, ensuring timely availability to healthcare providers and patients.

There is a notable increase in the incidence of cancers and genetic disorders in North America. This demographic trend drives the demand for molecular cytogenetic tests that can precisely diagnose chromosomal abnormalities associated with these diseases. Moreover, the emphasis on personalized medicine encourages the use of molecular cytogenetics to tailor treatment strategies based on individual genetic profiles.

North America is a hub for technological innovation in healthcare. The presence of leading market players, research institutions, and universities fosters continuous R&D in molecular cytogenetics. This results in the development of cutting-edge technologies and diagnostic assays that enhance accuracy, sensitivity, and efficiency in chromosomal analysis.

Asia Pacific

Asia Pacific is indeed experiencing rapid growth in the molecular cytogenetics market. Countries in Asia Pacific such as China, India, and Southeast Asian nations are witnessing significant increases in healthcare expenditure and improvements in healthcare infrastructure. This expansion supports greater accessibility to advanced diagnostic technologies, including molecular cytogenetics, across both urban and rural areas.

There is a notable rise in the prevalence of chronic diseases like cancer and genetic disorders in Asia Pacific. This demographic shift is fueling the demand for accurate and early diagnostic solutions provided by molecular cytogenetics. The ability to detect chromosomal abnormalities plays a crucial role in early intervention and personalized treatment planning.

The region is seeing rapid adoption of new technologies in healthcare, driven by increasing investments in research and development. This includes advancements in genomic technologies, automation in laboratory processes, and the integration of AI and machine learning in data analysis. These advancements enhance the capabilities and efficiency of molecular cytogenetic assays, making them more accessible and cost-effective.

Asia Pacific offers vast untapped market potential for molecular cytogenetics due to rising awareness about personalized medicine and genetic testing. As healthcare providers and patients become more informed about the benefits of genetic diagnostics, there is a growing willingness to invest in these technologies to improve healthcare outcomes.

Global Molecular Cytogenetics Market: Segmentation Analysis

The Global Molecular Cytogenetics Market is Segmented on the basis of Product, Technique, Application, And Geography.

Molecular Cytogenetics Market, By Product

• Kits & Reagent
• Instruments
• Consumables
• Software & Services

Based on Product, the Global Molecular Cytogenetics Market is bifurcated into Kits & Reagent, Instruments, Consumables, and Software & Services. In the molecular cytogenetics market, instruments emerge as the dominating product segment. These instruments include advanced equipment and platforms essential for performing molecular cytogenetic techniques such as Fluorescence In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), and array CGH. Instruments are crucial for automating and streamlining the process of chromosomal analysis, enhancing laboratory efficiency and accuracy. The continuous innovation in instrument technology, including improvements in resolution, sensitivity, and throughput, further solidifies their dominance in the market. As laboratories and research facilities worldwide upgrade their capabilities to meet the growing demand for molecular cytogenetic testing, instruments play a pivotal role in supporting these diagnostic and research applications. Software and services represent the rapidly growing segment within the molecular cytogenetics market.

Molecular Cytogenetics Market, By Technique

• Fluorescence In Situ Hybridization (FISH)
• Comparative Genomic Hybridization (CGH)
• Genomic In Situ Hybridization (GISH)
• Array Comparative Genomic Hybridization (ACGH)

Based on Technique, the Global Molecular Cytogenetics Market is bifurcated into Fluorescence In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Genomic In Situ Hybridization (GISH), Array Comparative Genomic Hybridization (ACGH). In the molecular cytogenetics market, Fluorescence In Situ Hybridization (FISH) stands out as the dominating technique due to its widespread adoption in both clinical diagnostics and research applications. FISH offers high specificity and sensitivity in detecting chromosomal abnormalities and genetic rearrangements, making it indispensable in identifying cancer biomarkers, diagnosing genetic disorders like Down syndrome, and monitoring disease progression. Its versatility across various clinical specialties, including oncology, prenatal diagnostics, and infectious diseases, contributes significantly to its dominance in the market. Comparative Genomic Hybridization (CGH) emerges as the rapidly growing segment within molecular cytogenetics.

Molecular Cytogenetics Market, By Application

• Genetic Disorders
• Oncology
• Personalized Medicine

Based on Application, the Global Molecular Cytogenetics Market is bifurcated into Genetic Disorders, Oncology, and Personalized Medicine. In the molecular cytogenetics market, oncology emerges as the dominating application segment due to its critical role in cancer diagnostics and treatment. Molecular cytogenetic techniques like Fluorescence In Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH) are extensively used to detect chromosomal abnormalities and genetic mutations associated with various types of cancer. These techniques enable oncologists to identify specific biomarkers, predict patient outcomes, and tailor personalized treatment strategies such as targeted therapies and immunotherapies. The increasing prevalence of cancer globally, coupled with advancements in genomic technologies, continues to drive the dominance of oncology as a key application in the molecular cytogenetics market. Personalized medicine represents the rapidly growing segment within molecular cytogenetics.

Molecular Cytogenetics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Molecular Cytogenetics Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the molecular cytogenetics market, North America stands out as the dominating geography, driven by advanced healthcare infrastructure, substantial investments in research and development, and a strong regulatory framework that supports innovation and commercialization of molecular cytogenetic products. The region's leadership is further bolstered by high prevalence rates of genetic disorders and cancers, which spur demand for advanced diagnostic solutions using techniques such as Fluorescence In Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH). Moreover, North America's proactive adoption of personalized medicine approaches contributes to the market's dominance, as healthcare providers increasingly rely on molecular cytogenetics for tailored treatment strategies and improved patient outcomes. Asia Pacific represents the rapidly growing segment in the molecular cytogenetics market, fueled by increasing healthcare expenditures, expanding healthcare infrastructure, and rising awareness about genetic testing and personalized medicine across countries like China, India, and Southeast Asian nations.

Key Players

• The "Global Molecular Cytogenetics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Abbott Laboratories, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, Leica Biosystems Nussloch GmbH, CytoTest, Inc., Bionano Genomics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Molecular Cytogenetics Market Key Developments

• In June 2023, Thermo Fisher Scientific launched a new generation of FISH probes with enhanced specificity and sensitivity for detecting chromosomal abnormalities associated with cancer and genetic disorders. These advanced probes are designed to improve diagnostic accuracy and support personalized medicine approaches.
• In September 2022, Agilent Technologies introduced a next-generation array CGH platform capable of high-resolution genome-wide analysis. The platform integrates advanced bioinformatics tools for comprehensive genomic profiling, enabling researchers and clinicians to identify genetic variations linked to various diseases.
• In March 2022, PerkinElmer announced the expansion of its molecular cytogenetics portfolio with the introduction of automated FISH assay systems. These systems streamline laboratory workflows, reduce hands-on time, and enhance throughput for high-volume diagnostic testing, particularly in oncology and prenatal diagnostics.
• In December 2021, Illumina Inc. launched a new software platform for analyzing CGH data from its sequencing systems. The platform includes AI-powered algorithms for interpreting complex genomic data, providing researchers with actionable insights into chromosomal abnormalities and structural variations.
• In August 2021, Oxford Gene Technology (OGT) introduced novel genomic in situ hybridization (GISH) probes for studying plant genomes. These probes enable researchers to visualize and analyze chromosomal organization and genetic variation in plants, supporting advancements in agricultural biotechnology.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Molecular Cytogenetics Market, By Product

• Kits & Reagents
• Instruments
• Consumables
• Software & Services

5. Molecular Cytogenetics Market, By Technique

• Fluorescence In Situ Hybridization (FISH)
• Comparative Genomic Hybridization (CGH)
• Genomic In Situ Hybridization (GISH)
• Array Comparative Genomic Hybridization (ACGH)

6. Molecular Cytogenetics Market, By Application

• Genetic Disorders
• Oncology
• Personalized Medicine

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Agilent Technologies, Inc.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Oxford Gene Technology IP Limited
• Leica Biosystems Nussloch GmbH
• CytoTest Inc.
• Cytognomix, Inc.
• Bionano Genomics

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References